Global Enzyme Immunoassay (EIA) Reagents and Devices Market is Growing at a Significant Rate in the Forecast Period 2018-2025
According to Data Bridge Market Research new Market report, “Global Enzyme Immunoassay (EIA) Reagents and Devices Market” is projected to reach USD 11.28 billion by 2025, at a CAGR of 4.2% during the forecast period of 2018 to 2025.
(EMAILWIRE.COM, October 01, 2018 ) According to Data Bridge Market Research new Market report, “Global Enzyme Immunoassay (EIA) Reagents and Devices Market” By Technology(Enzyme Immunoassays, Fluorescent Immunoassays, Chemiluminescence Immunoassays, Radioimmunoassay, and Others), By product type(Analyzers, Reagents),By Application(Oncology, Infectious Diseases, Cardiology, Bone and Mineral, Endocrinology, Autoimmunity, Toxicology, hematology, neonatal screening, and others),By End-Users(Hospitals, Laboratories, Academics, Pharmaceutical Industries {CRO’s, Biotech}, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast is projected to reach USD 11.28 billion by 2025, at a CAGR of 4.2% during the forecast period of 2018 to 2025.
Get free sample @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-enzyme-immunoassay-eia-reagents-and-devices-market
Global Enzyme Immunoassay Reagents and Devices Market
Enzyme Immunoassay (EIA) Reagents and Devices are used to detect the presence of antigen or concentration of an analyteswith its applicability to epidemiological diseases detection and vaccine trials. The basic use is for measurement of drugs, hormones, specific proteins, tumor markers, and markers of cardiac injury. Enzyme immunoassay (EIA) Reagents associated Devices are accustomed discover the presence of substance or concentration of an enzyme with its pertinence to epidemiologic diseases detection and immunizing agent trials.
Immunoassays generally fall into two categories. First, antibody-antigen precipitation tests, such as radial immunodiffusion, hemagglutination, and coated latex particle agglutination. Second, labeled-reagent tests, such as radioimmunoassay, and enzyme-linked immunoassay.
Enzyme immunoassays (EIAs), also known as enzyme-linked immunosorbent assays (ELISAs), combine antibody binding with enzymatic detection to quantify molecules of interest. EIAs are easy to perform, require little specialized equipment, and both the experienced lab technician and the research lab novice can learn EIA skills quickly. EIA is often regarded as the test used to detect HIV.
The enzyme-linked immunosorbent assay (ELISA) is a diagnostic test that uses antibodies and color change to identify a substance. The ELISA has been used as a diagnostic tool in medicine and plant pathology, as well as a quality-control check in various industries. Antigens from the sample are attached to a surface. Then, a further specific antibody is applied over the surface so it can bind to the antigen. This antibody is linked to an enzyme, and, in the final step, a substance containing the enzyme’s substrate is added. The subsequent reaction produces a detectable signal, most commonly a color change in the substrate.
Rapid diagnostic tests allowing for the qualitative and quantitative determination of a number of differing analytes hold great potential for acceptance by both laboratory and field personnel. In the clinical laboratory, rapid, sensitive, specific and accurate tests based upon the presence or absence of analyte in biological specimens provide possibilities for the early detection, confirmed diagnosis, and prompt treatment for many pathological conditions. In the field, the potential use of such tests may be extended to determine the presence or absence of differing analytes in air, food, water or soil.
The advantage and acceptance of the diagnostic devices and kits to perform such rapid analysis depends on a number of factors such as sensitivity, specificity, cost per test, ease of use, and timeliness of test results. Ideally, to be accepted by the user, such a device or kit should be simple to perform with rapid, easy to interpret and virtually foolproof results. In addition, such a device should be easily transportable, capable of providing the results of the test “on site”, and disposable after use.
Enzyme immunoassay has wide range of application in clinical laboratories and one of the largest application is related to the detections of viruses. For example, the screening and diagnosis of hepatitis virus is routinely used in the lab. These include the detection of HBsAg and HBeAg by direct ELISA, anti-HBc antibody and anti-HBe antibody by competitive ELISA and anti-HBs antibody by indirect ELISA. What is more, ELISA can detect HCV antibodies in serum samples as screening tests and the positive samples are conformed by molecular HCV RNA.
The Advantageous effect of using an enzyme immunoassay in clinical hematology is that it got the ability to identify alloantibodies in patients who frequently receive platelet transfusions for therapeutic purposes. It has been demonstrated that ELISA is more sensitive to the detection of alloantibodies than other immunoassays, such as Lymphocytotoxic Test (LCT) and the Platelet Immunofluorescence Test (PIFT), and it is performed in a short period of time. Furthermore, enzyme immunoassays are able to detect anti-platelet antibodies, Platelet Associated IgG (PAIgG) , HLA and circulating antibodies in patients with Idiopathic Thrombocytopenic Purpura (ITP).
There are various evidence which suggest that a ubiquitous herpes virus, in particular Epstein-Barr virus (EBV), is implicated in many types of lymphoma such as Hodgkin’s disease and Burkitt’s lymphoma, so the early detection of EBV antigen specific T cells is essential and therefore ELISPOT assay can be used to analyse T cell responses.
Another of its feature is related to acquire von Willebrand syndrome, which is caused by autoantibodies against von Willebrand factor (vWF). This plays an essential role in hemostasis and is characterized by prolonged bleeding due to the defect in vWF activity. Detection of anti-vWF antibody can be performed by ELISA (Mohri 2003), mention that competitive ELISA is a useful technique in the detection of anti-vWFA antibodies in a clinical samples.
Despite the benefits of ELISA in the detection of HLA class I specific antibodies, it is less sensitive than flow cytometry, so before platelet transplantation, flow cytometry must be used. Although chemiluminescence immunoassay has great sensitivity in detecting HBsAg in blood donor samples, it has less sensitivity than the polymerase chain reaction (PCR), so to increase the safety of blood from HIV-1 , HCV, and HBV, the nucleic acid amplification technique (NAT) has been applied for the screening of blood donor samples.
Inquire before buying @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-enzyme-immunoassay-eia-reagents-and-devices-market
Market Segmentation: Global Enzyme Immunoassay Reagents and Devices Market
The global market for Enzyme immunoassay reagents and device by the following sub-categories is presented
• By Technology
o Enzyme immunoassays
o Fluorescent immunoassays
o Chemiluminescence immunoassays
o Radioimmunoassay and others
• By product type
o Analyzers
o Reagents
• By Application
o Oncology
o Infectious diseases
o Cardiology
o Bone and Mineral
o Endocrinology
o Autoimmunity
o Toxicology
o Hematology
o Neonatal Screening
o Others
• By End-Users
o Hospitals
o Laboratories
o Academics
o Pharmaceutical Industries
o Others
• By Geography
o North America
o South America
o Europe
o Asia-Pacific
o Middle East and Africa
FACTORS DRIVING GROWTH IN THE GLOBAL ENZYME IMMUNOASSAY REAGENTS AND DEVICES MARKET:
Rising Usage of Novel Biomarkers and Innovative Technologies:
Biomarkers represent powerful tools for diseases detection, determining the efficacy and safety of novel therapeutic agents and monitoring disease recurrence.
Identification of key biomarkers at early stages of diseases that can be easily obtained by the least invasive methods is critical for early diagnosis of cancer diagnosis. Human body fluids, such as blood, present a promising resource for biomarkers. Routine detection of biomarkers is critical to bring substantial advances in molecular medicine and transform many areas of medicine from clinical trials to diagnosis and treatment of complex diseases.
Survival of cancer patients depends heavily on early detection and therefore, developing new technologies allows for a quick, sensitive and cost effective method is critical for cancer research . Early detection is an important factor in determining the survival of patients with hepatocellular carcinoma (HCC). However, early diagnosis of cancer is still difficult to achieve due to the lack of specific symptoms in early stages of the disease where detection of biomarkers is still unattainable due to low detection levels.
Recent advances in detection technologies hold promises to identify novel biomarkers reliably and accurately to predict outcomes during cancer treatment and management. Additionally, the new technologies provide higher analytical capabilities, employing automated liquid handling systems for greater sensitivity, more robust and higher throughput sample analysis.
Rising Incidence of Chronic and Infectious Diseases:
The last half century has seen a steady increase in the incidence and prevalence of chronic inflammatory diseases with further increases expected. This may be due to number of factors such as:
• Misuse of antibiotics especially Beta-lactam antibiotics
• Vitamin supplementation including folic acid but especially vitamin D
• Presence of environmental factors which suppress immunity
• Novel vectors for sharing pathogens including blood donation
• Widespread adoption of compulsory mass vaccinations
Chronic diseases are the largest cause of death in the world. The leading chronic diseases—cardiovascular disease, cancer, chronic respiratory disease, and diabetes—caused 29 million deaths worldwide. Annual mortality due to chronic disease is expected to increase in real numbers as well as relative to deaths from injuries and diseases traditionally understood to be infectious such as polio, rubella, tuberculosis, etc.
The 2014 Ebola outbreak in West Africa dramatically raised awareness of the global burden of infectious disease and raised questions about the preparedness of public health systems. In February 2016, the public scrambled to understand the implications of the Zika virus after the World Health Organization designated it as an international public health emergency because of the suspected relationship between Zika and a rise in cases of a rare congenital condition called microcephaly in Brazil. Although non-communicable diseases are the leading cause of morbidity and mortality in most developed nations, infectious disease remains a major public health concern in the United States and around the world.
A 2014 report by the U.S. Centers for Disease Control and Prevention found that salmonella was responsible for more cases of illness, hospitalizations and deaths than any other food-borne pathogen. A 2012 study published in Lancet Infectious Diseases reviews non-infectious disease risks from mass-gatherings. A 2011 report by the World Health Organization reviewed the causes of death globally, and identified ways by which to measure progress in infectious disease, among other types and indicators of morbidity and mortality.
Some of the major players operating in Enzyme Immunoassay (EIA) Reagents and devicesmarket are
• Novozymes,
• DSM,
• DuPont ,
• Siemens,
• Roche Diagnostics,
• Abbott Laboratories,
• Danaher Corporation,
• Ortho Clinical Diagnostics,
• BioMerieux,
• Randox Laboratories Ltd,
• Biohit Oyj,
• Meril Life Sciences Pvt. Ltd,
• Tosoh Corporation,
• Inova Diagnostics,
• IASON GmbH,
• Radiometer Medical ApS ,
• Lifotronic Technology Co., Ltd,
• PerkinElmer Inc,
• Molecular Devices, LLC ,
• bioMérieux SA,
• HYCOR Biomedical.
Access Full Report: http://databridgemarketresearch.com/reports/global-hla-typing-transplant-diagnostics-services-market/
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com
Get free sample @ https://databridgemarketresearch.com/request-a-sample/?dbmr=global-enzyme-immunoassay-eia-reagents-and-devices-market
Global Enzyme Immunoassay Reagents and Devices Market
Enzyme Immunoassay (EIA) Reagents and Devices are used to detect the presence of antigen or concentration of an analyteswith its applicability to epidemiological diseases detection and vaccine trials. The basic use is for measurement of drugs, hormones, specific proteins, tumor markers, and markers of cardiac injury. Enzyme immunoassay (EIA) Reagents associated Devices are accustomed discover the presence of substance or concentration of an enzyme with its pertinence to epidemiologic diseases detection and immunizing agent trials.
Immunoassays generally fall into two categories. First, antibody-antigen precipitation tests, such as radial immunodiffusion, hemagglutination, and coated latex particle agglutination. Second, labeled-reagent tests, such as radioimmunoassay, and enzyme-linked immunoassay.
Enzyme immunoassays (EIAs), also known as enzyme-linked immunosorbent assays (ELISAs), combine antibody binding with enzymatic detection to quantify molecules of interest. EIAs are easy to perform, require little specialized equipment, and both the experienced lab technician and the research lab novice can learn EIA skills quickly. EIA is often regarded as the test used to detect HIV.
The enzyme-linked immunosorbent assay (ELISA) is a diagnostic test that uses antibodies and color change to identify a substance. The ELISA has been used as a diagnostic tool in medicine and plant pathology, as well as a quality-control check in various industries. Antigens from the sample are attached to a surface. Then, a further specific antibody is applied over the surface so it can bind to the antigen. This antibody is linked to an enzyme, and, in the final step, a substance containing the enzyme’s substrate is added. The subsequent reaction produces a detectable signal, most commonly a color change in the substrate.
Rapid diagnostic tests allowing for the qualitative and quantitative determination of a number of differing analytes hold great potential for acceptance by both laboratory and field personnel. In the clinical laboratory, rapid, sensitive, specific and accurate tests based upon the presence or absence of analyte in biological specimens provide possibilities for the early detection, confirmed diagnosis, and prompt treatment for many pathological conditions. In the field, the potential use of such tests may be extended to determine the presence or absence of differing analytes in air, food, water or soil.
The advantage and acceptance of the diagnostic devices and kits to perform such rapid analysis depends on a number of factors such as sensitivity, specificity, cost per test, ease of use, and timeliness of test results. Ideally, to be accepted by the user, such a device or kit should be simple to perform with rapid, easy to interpret and virtually foolproof results. In addition, such a device should be easily transportable, capable of providing the results of the test “on site”, and disposable after use.
Enzyme immunoassay has wide range of application in clinical laboratories and one of the largest application is related to the detections of viruses. For example, the screening and diagnosis of hepatitis virus is routinely used in the lab. These include the detection of HBsAg and HBeAg by direct ELISA, anti-HBc antibody and anti-HBe antibody by competitive ELISA and anti-HBs antibody by indirect ELISA. What is more, ELISA can detect HCV antibodies in serum samples as screening tests and the positive samples are conformed by molecular HCV RNA.
The Advantageous effect of using an enzyme immunoassay in clinical hematology is that it got the ability to identify alloantibodies in patients who frequently receive platelet transfusions for therapeutic purposes. It has been demonstrated that ELISA is more sensitive to the detection of alloantibodies than other immunoassays, such as Lymphocytotoxic Test (LCT) and the Platelet Immunofluorescence Test (PIFT), and it is performed in a short period of time. Furthermore, enzyme immunoassays are able to detect anti-platelet antibodies, Platelet Associated IgG (PAIgG) , HLA and circulating antibodies in patients with Idiopathic Thrombocytopenic Purpura (ITP).
There are various evidence which suggest that a ubiquitous herpes virus, in particular Epstein-Barr virus (EBV), is implicated in many types of lymphoma such as Hodgkin’s disease and Burkitt’s lymphoma, so the early detection of EBV antigen specific T cells is essential and therefore ELISPOT assay can be used to analyse T cell responses.
Another of its feature is related to acquire von Willebrand syndrome, which is caused by autoantibodies against von Willebrand factor (vWF). This plays an essential role in hemostasis and is characterized by prolonged bleeding due to the defect in vWF activity. Detection of anti-vWF antibody can be performed by ELISA (Mohri 2003), mention that competitive ELISA is a useful technique in the detection of anti-vWFA antibodies in a clinical samples.
Despite the benefits of ELISA in the detection of HLA class I specific antibodies, it is less sensitive than flow cytometry, so before platelet transplantation, flow cytometry must be used. Although chemiluminescence immunoassay has great sensitivity in detecting HBsAg in blood donor samples, it has less sensitivity than the polymerase chain reaction (PCR), so to increase the safety of blood from HIV-1 , HCV, and HBV, the nucleic acid amplification technique (NAT) has been applied for the screening of blood donor samples.
Inquire before buying @ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-enzyme-immunoassay-eia-reagents-and-devices-market
Market Segmentation: Global Enzyme Immunoassay Reagents and Devices Market
The global market for Enzyme immunoassay reagents and device by the following sub-categories is presented
• By Technology
o Enzyme immunoassays
o Fluorescent immunoassays
o Chemiluminescence immunoassays
o Radioimmunoassay and others
• By product type
o Analyzers
o Reagents
• By Application
o Oncology
o Infectious diseases
o Cardiology
o Bone and Mineral
o Endocrinology
o Autoimmunity
o Toxicology
o Hematology
o Neonatal Screening
o Others
• By End-Users
o Hospitals
o Laboratories
o Academics
o Pharmaceutical Industries
o Others
• By Geography
o North America
o South America
o Europe
o Asia-Pacific
o Middle East and Africa
FACTORS DRIVING GROWTH IN THE GLOBAL ENZYME IMMUNOASSAY REAGENTS AND DEVICES MARKET:
Rising Usage of Novel Biomarkers and Innovative Technologies:
Biomarkers represent powerful tools for diseases detection, determining the efficacy and safety of novel therapeutic agents and monitoring disease recurrence.
Identification of key biomarkers at early stages of diseases that can be easily obtained by the least invasive methods is critical for early diagnosis of cancer diagnosis. Human body fluids, such as blood, present a promising resource for biomarkers. Routine detection of biomarkers is critical to bring substantial advances in molecular medicine and transform many areas of medicine from clinical trials to diagnosis and treatment of complex diseases.
Survival of cancer patients depends heavily on early detection and therefore, developing new technologies allows for a quick, sensitive and cost effective method is critical for cancer research . Early detection is an important factor in determining the survival of patients with hepatocellular carcinoma (HCC). However, early diagnosis of cancer is still difficult to achieve due to the lack of specific symptoms in early stages of the disease where detection of biomarkers is still unattainable due to low detection levels.
Recent advances in detection technologies hold promises to identify novel biomarkers reliably and accurately to predict outcomes during cancer treatment and management. Additionally, the new technologies provide higher analytical capabilities, employing automated liquid handling systems for greater sensitivity, more robust and higher throughput sample analysis.
Rising Incidence of Chronic and Infectious Diseases:
The last half century has seen a steady increase in the incidence and prevalence of chronic inflammatory diseases with further increases expected. This may be due to number of factors such as:
• Misuse of antibiotics especially Beta-lactam antibiotics
• Vitamin supplementation including folic acid but especially vitamin D
• Presence of environmental factors which suppress immunity
• Novel vectors for sharing pathogens including blood donation
• Widespread adoption of compulsory mass vaccinations
Chronic diseases are the largest cause of death in the world. The leading chronic diseases—cardiovascular disease, cancer, chronic respiratory disease, and diabetes—caused 29 million deaths worldwide. Annual mortality due to chronic disease is expected to increase in real numbers as well as relative to deaths from injuries and diseases traditionally understood to be infectious such as polio, rubella, tuberculosis, etc.
The 2014 Ebola outbreak in West Africa dramatically raised awareness of the global burden of infectious disease and raised questions about the preparedness of public health systems. In February 2016, the public scrambled to understand the implications of the Zika virus after the World Health Organization designated it as an international public health emergency because of the suspected relationship between Zika and a rise in cases of a rare congenital condition called microcephaly in Brazil. Although non-communicable diseases are the leading cause of morbidity and mortality in most developed nations, infectious disease remains a major public health concern in the United States and around the world.
A 2014 report by the U.S. Centers for Disease Control and Prevention found that salmonella was responsible for more cases of illness, hospitalizations and deaths than any other food-borne pathogen. A 2012 study published in Lancet Infectious Diseases reviews non-infectious disease risks from mass-gatherings. A 2011 report by the World Health Organization reviewed the causes of death globally, and identified ways by which to measure progress in infectious disease, among other types and indicators of morbidity and mortality.
Some of the major players operating in Enzyme Immunoassay (EIA) Reagents and devicesmarket are
• Novozymes,
• DSM,
• DuPont ,
• Siemens,
• Roche Diagnostics,
• Abbott Laboratories,
• Danaher Corporation,
• Ortho Clinical Diagnostics,
• BioMerieux,
• Randox Laboratories Ltd,
• Biohit Oyj,
• Meril Life Sciences Pvt. Ltd,
• Tosoh Corporation,
• Inova Diagnostics,
• IASON GmbH,
• Radiometer Medical ApS ,
• Lifotronic Technology Co., Ltd,
• PerkinElmer Inc,
• Molecular Devices, LLC ,
• bioMérieux SA,
• HYCOR Biomedical.
Access Full Report: http://databridgemarketresearch.com/reports/global-hla-typing-transplant-diagnostics-services-market/
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com
Contact Information:
Data Bridge Market Research
Data Bridge Market Research
Tel: +1-888-387-2818
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Data Bridge Market Research
Data Bridge Market Research
Tel: +1-888-387-2818
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results